Format

Send to

Choose Destination
Future Cardiol. 2012 Nov;8(6):895-912. doi: 10.2217/fca.12.68.

The impact of current and novel anti-diabetic therapies on cardiovascular risk.

Author information

1
Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Canada. ussher@lunenfeld.ca

Abstract

Type 2 diabetes mellitus (T2DM) has become an overwhelming health condition that is no longer just a threat to developed nations, but to undeveloped nations as well. Current therapies for T2DM are relatively effective in controlling hyperglycemia; examples include metformin, thiazolidinediones, sulfonylurea derivatives, α-glucosidase inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Despite their efficacy in controlling hyperglycemia, due to recent findings of increased cardiovascular risk following treatment with either rosiglitazone or intensive glucose lowering, new guidelines from the US FDA recommend that new therapies for diabetes not only improve glycemia, but exert no adverse cardiovascular effects. Based on cardiovascular risk profiles, metformin appears to be the superior anti-diabetic therapy, although studies in humans with glucagon-like peptide-1 receptor agonists are encouraging. As patients with T2DM also often have cardiovascular disease, the increased rigor in drug development should ultimately reduce the health burden of both of these conditions.

PMID:
23176691
DOI:
10.2217/fca.12.68
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center